{"id":640761,"date":"2023-03-01T19:56:02","date_gmt":"2023-03-01T19:56:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=640761"},"modified":"2023-03-01T19:56:02","modified_gmt":"2023-03-01T19:56:02","slug":"antihyperlipidemic-drugs-market-size-expected-to-reach-us-160-billion-by-2028-industry-growth-rate-cagr-of-46","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/antihyperlipidemic-drugs-market-size-expected-to-reach-us-160-billion-by-2028-industry-growth-rate-cagr-of-46_640761.html","title":{"rendered":"Antihyperlipidemic Drugs Market Size Expected to Reach US$ 16.0 Billion by 2028, Industry Growth Rate (CAGR) of 4.6%"},"content":{"rendered":"
\n
\"Antihyperlipidemic<\/a><\/div>\n
\n
Antihyperlipidemic Drugs Market Report 2023-2028<\/div>\n<\/div>\n<\/div>\n
The global antihyperlipidemic drugs market size reached US$ 12.0 Billion in 2022. By 2028, it will reach a value of US$ 16.0 Billion, growing at 4.6% 2023-2028.<\/div>\n

IMARC Group latest research study “Antihyperlipidemic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028<\/strong>”, the global antihyperlipidemic drugs market size reached US$ 12.0 Billion in 2022<\/strong>. Looking forward, the market is expected to reach US$ 16.0 Billion by 2028<\/strong>, exhibiting a growth rate (CAGR) of 4.6%<\/strong><\/a> during 2023-2028.<\/p>\n

What Are Antihyperlipidemic Drugs in Market?<\/strong><\/p>\n

Antihyperlipidemic drugs are medications used to lower serum levels of cholesterol and lipids (fats) in the blood. Some of the commonly available antihyperlipidemic drugs include bile acid sequestrants, fabric acid derivatives, cholesterol absorption inhibitors, antihyperlipidemic agents, PCSK9 inhibitors, and statins. They are prescribed along with different medications to manage lipid levels in the blood of patients, which can cause various diseases, such as hypertension, diabetes, obesity, and hyperlipidemia. In addition, these drugs help to increase the high-density lipoprotein (HDL) cholesterol in the body to prevent coronary heart conditions.<\/p>\n

Request a PDF Sample for more detailed market insights: <\/strong>https:\/\/www.imarcgroup.com\/antihyperlipidemic-drugs-market\/requestsample<\/strong><\/a><\/p>\n

Antihyperlipidemic Drugs Market Trends and Drivers:<\/strong><\/p>\n

The market is primarily driven by the rising prevalence of hyperlipidemia among individuals due to sedentary lifestyles, consumption of fast foods, and nicotine addiction. In addition, the increasing geriatric population that is more susceptible to developing cardiovascular diseases is contributing to market growth.<\/p>\n

Moreover, the increasing incidences of several medical conditions such as diabetes, pregnancy, kidney, and peripheral artery diseases that are likely to result in hyperlipidemia represent another major growth-inducing factor. Besides this, there has been escalated product demand due to the growing prevalence of genetic and acquired lipid and lipoprotein metabolism disorders among the pediatric population to reduce hospitalization rates and premature deaths.<\/p>\n

Furthermore, antihyperlipidemic drugs are widely prescribed for reducing low-density lipoprotein (LDL) cholesterol and increasing high-density lipoprotein (HDL) to minimize the risk of coronary artery disease (CAD) in individuals, which is creating a positive market outlook across the globe.<\/p>\n\n\n\n\n\n\n\n\n\n\n
\n

Antihyperlipidemic Drugs Market Report Scope<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

Report Coverage<\/strong><\/p>\n<\/td>\n

\n

Details<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

Market size value in 2022<\/p>\n<\/td>\n

\n

US$ 12.0 Billion<\/p>\n<\/td>\n<\/tr>\n

\n

Market forecast in 2028<\/p>\n<\/td>\n

\n

US$ 16.0 Billion<\/p>\n<\/td>\n<\/tr>\n

\n

Growth Rate<\/p>\n<\/td>\n

\n

CAGR of 4.6% from 2023 to 2028<\/p>\n<\/td>\n<\/tr>\n

\n

Base year for estimation<\/p>\n<\/td>\n

\n

2022<\/p>\n<\/td>\n<\/tr>\n

\n

Historical data<\/p>\n<\/td>\n

\n

2017-2022<\/p>\n<\/td>\n<\/tr>\n

\n

Forecast period<\/p>\n<\/td>\n

\n

2023-2028<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n


Global Antihyperlipidemic Drugs Market 2023-2028 Analysis and Segmentation:<\/strong><\/p>\n


Competitive Landscape:<\/strong><\/p>\n

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.<\/p>\n


Antihyperlipidemic Drugs Companies: <\/strong><\/p>\n

Amgen Inc. (NASDAQ: AMGN)<\/p>\n

AstraZeneca plc (LON: AZN)<\/p>\n

Daiichi Sankyo Company Limited (TYO: 4568)<\/p>\n

Merck & Co. Inc.<\/p>\n

Novartis AG<\/p>\n

Pfizer Inc.<\/p>\n

Sanofi S.A.<\/p>\n

The report has segmented the market on the basis of region, drug class, route of administration and distribution channel.<\/p>\n

Breakup by Drug Class:<\/strong><\/p>\n